Bree R Eaton1, Natia Esiashvili1, Sungjin Kim1, Briana Patterson1, Elizabeth A Weyman1, Lauren T Thornton1, Claire Mazewski1, Tobey J MacDonald1, David Ebb1, Shannon M MacDonald1, Nancy J Tarbell1, Torunn I Yock1. 1. Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia (B.R.E., N.E.); Pediatrics, Emory University School of Medicine and Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia (B.P., C.M., T.J.M.); Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California (S.K.); Pediatrics, Massachusetts General Hospital, Boston, Massachusetts (D.E.); Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (B.R.E., E.A.W., L.T.T., S.M.M., N.J.T., T.I.Y.).
Abstract
BACKGROUND: Endocrine dysfunction is a common sequela of craniospinal irradiation (CSI). Dosimetric data suggest that proton radiotherapy (PRT) may reduce radiation-associated endocrine dysfunction but clinical data are limited. METHODS: Seventy-seven children were treated with chemotherapy and proton (n = 40) or photon (n = 37) radiation between 2000 and 2009 with ≥3 years of endocrine screening. The incidence of multiple endocrinopathies among the proton and photon cohorts is compared. Multivariable analysis and propensity score adjusted analysis are performed to estimate the effect of radiotherapy type while adjusting for other variables. RESULTS: The median age at diagnosis was 6.2 and 8.3 years for the proton and photon cohorts, respectively (P = .010). Cohorts were similar with respect to gender, histology, CSI dose, and total radiotherapy dose and whether the radiotherapy boost was delivered to the posterior fossa or tumor bed. The median follow-up time was 5.8 years for proton patients and 7.0 years for photon patients (P = .010). PRT was associated with a reduced risk of hypothyroidism (23% vs 69%, P < .001), sex hormone deficiency (3% vs 19%, P = .025), requirement for any endocrine replacement therapy (55% vs 78%, P = .030), and a greater height standard deviation score (mean (± SD) -1.19 (± 1.22) vs -2 (± 1.35), P = .020) on both univariate and multivariate and propensity score adjusted analysis. There was no significant difference in the incidence of growth hormone deficiency (53% vs 57%), adrenal insufficiency (5% vs 8%), or precocious puberty (18% vs 16%). CONCLUSIONS: Proton radiotherapy may reduce the risk of some, but not all, radiation-associated late endocrine abnormalities.
BACKGROUND:Endocrine dysfunction is a common sequela of craniospinal irradiation (CSI). Dosimetric data suggest that proton radiotherapy (PRT) may reduce radiation-associated endocrine dysfunction but clinical data are limited. METHODS: Seventy-seven children were treated with chemotherapy and proton (n = 40) or photon (n = 37) radiation between 2000 and 2009 with ≥3 years of endocrine screening. The incidence of multiple endocrinopathies among the proton and photon cohorts is compared. Multivariable analysis and propensity score adjusted analysis are performed to estimate the effect of radiotherapy type while adjusting for other variables. RESULTS: The median age at diagnosis was 6.2 and 8.3 years for the proton and photon cohorts, respectively (P = .010). Cohorts were similar with respect to gender, histology, CSI dose, and total radiotherapy dose and whether the radiotherapy boost was delivered to the posterior fossa or tumor bed. The median follow-up time was 5.8 years for proton patients and 7.0 years for photon patients (P = .010). PRT was associated with a reduced risk of hypothyroidism (23% vs 69%, P < .001), sex hormone deficiency (3% vs 19%, P = .025), requirement for any endocrine replacement therapy (55% vs 78%, P = .030), and a greater height standard deviation score (mean (± SD) -1.19 (± 1.22) vs -2 (± 1.35), P = .020) on both univariate and multivariate and propensity score adjusted analysis. There was no significant difference in the incidence of growth hormone deficiency (53% vs 57%), adrenal insufficiency (5% vs 8%), or precocious puberty (18% vs 16%). CONCLUSIONS: Proton radiotherapy may reduce the risk of some, but not all, radiation-associated late endocrine abnormalities.
Authors: Briana C Patterson; Lauren Truxillo; Karen Wasilewski-Masker; Ann C Mertens; Lillian R Meacham Journal: Pediatr Blood Cancer Date: 2009-12-15 Impact factor: 3.167
Authors: Christine Lauro; Margaret E Macy; Philip Zeitler; Jennifer Backus; Pamela Mettler; Nicholas Foreman; Arthur K Liu Journal: J Pediatr Endocrinol Metab Date: 2014-03 Impact factor: 1.634
Authors: Thomas E Merchant; Susan R Rose; Christina Bosley; Shengjie Wu; Xiaoping Xiong; Robert H Lustig Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: W H St Clair; J A Adams; M Bues; B C Fullerton; Sean La Shell; H M Kooy; J S Loeffler; N J Tarbell Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Stephen J Laughton; Thomas E Merchant; Charles A Sklar; Larry E Kun; Maryam Fouladi; Alberto Broniscer; E Brannon Morris; Robert P Sanders; Matthew J Krasin; John Shelso; Zang Xiong; Dana Wallace; Amar Gajjar Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Ralph E Vatner; Andrzej Niemierko; Madhusmita Misra; Elizabeth A Weyman; Claire P Goebel; David H Ebb; Robin M Jones; Mary S Huang; Anita Mahajan; David R Grosshans; Arnold C Paulino; Takara Stanley; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2018-08-17 Impact factor: 44.544
Authors: Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300